Combined Modality Therapy

3 trials

Sponsors

Center of Molecular Immunology (CIM), Cancerology State Institute, Colima State Health Service (SSA-Colima), Mexico, Center for Genetic Engineering and Biotechnology (CIGB), in Havana

Conditions

Cervical cancerCervical cancer in stages IB2 and II.Inoperable esophageal tumors of epithelial origin, located in cervical esophagus or intra-thoracic (upper thoracic portion or half) of new diagnosis, relapse or progression. inoperable tumors of the esophagus

Phase 2

Paclitaxel/Radiotherapy/Cisplatino for cervical cancer

Active, not recruitingRPCEC00000239

Cancerology State Institute, Colima State Health Service (SSA-Colima), MexicoCervical cancer

Start: 2017-03-07Target: 30Updated: 2026-03-30

Phase 3

CERVICONC-II-300 study

Active, not recruitingRPCEC00000285

Center for Genetic Engineering and Biotechnology (CIGB), in HavanaCervical cancer in stages IB2 and II.

Start: 2018-10-01Target: 144Updated: 2026-03-30

Phase 4

Nimotuzumab inoperable esophageal epithelial tumors, Phase IV

Active, not recruitingRPCEC00000215

Center of Molecular Immunology (CIM)Inoperable esophageal tumors of epithelial origin, located in cervical esophagus or intra-thoracic (upper thoracic portion or half) of new diagnosis, relapse or progression. inoperable tumors of the esophagus

Start: 2016-07-15Updated: 2026-03-30

Related Papers

Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin

Journal of Oncology2022-09-012 citations